Asthma: Spiriva® (tiotropium) Respimat® becomes the only LAMA licensed in asthma care
1 October 2014 | By Boehringer Ingelheim
Boehringer Ingelheim announced that adult asthma patients could benefit from a new treatment...
List view / Grid view
1 October 2014 | By Boehringer Ingelheim
Boehringer Ingelheim announced that adult asthma patients could benefit from a new treatment...
8 September 2014 | By Boehringer Ingelheim
Boehringer Ingelheim announced that the indication for Spiriva® (tiotropium) Respimat®* in asthma has been accepted by the regulatory authorities in the EU...
1 September 2014 | By Boehringer Ingelheim
The European Respiratory Society International Congress, in Munich, Germany, September 6-10, 2014 sets the scene for important announcements across the substantial Boehringer Ingelheim respiratory portfolio...
20 May 2014 | By Boehringer Ingelheim
Data analyses presented at the Annual American Thoracic Society International Conference 2014 reconfirm the efficacy of SPIRIVA® (tiotropium) in reducing the risk of COPD exacerbations...
13 November 2013 | By Boehringer Ingelheim
"Our extensive studies have demonstrated that tiotropium Respimat® has the potential to be an effective new treatment..."
9 September 2013 | By Boehringer Ingelheim
TIOSPIR™, with over 17,000 COPD patients included and one of the largest international COPD trials ever conducted...
3 September 2012 | By Boehringer Ingelheim
SPIRIVA® is the most prescribed COPD maintenance treatment worldwide...